Aberrations within the RAS-MAPK pathway are well-known in relapsed NB and finding the topoisomerase inhibitors topotecan and irinotecan as synergistic candidates in our study suggest that adding CHK1 inhibition to existing treatment protocols could potentially be beneficial for relapsed or refractory NB patients (47). This evidence concerns the gene CHEK1 and neuroblastoma.